AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

New York, New York--(Newsfile Corp. - March 26, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Astrazeneca Plc (NASDAQ: AZN) alleging that the Company violated federal securities laws.Class Period: May 21, 2020 and November 20, 2020Lead Plaintiff Deadline: March 29, 2021Learn more about your recoverable losses in AZN:

AZN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 29, 2021 in the Class Action Filed on Behalf of Astrazeneca Plc Limited Shareholders

Los Angeles, California--(Newsfile Corp. - March 26, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive (the...

DEADLINE MONDAY ALERT: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - March 26, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Astrazeneca Plc ("Astrazeneca") (NYSE: AZN) between May 21, 2020 and November 20, 2020.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/astrazeneca-plc-loss-submission-form?prid=14159&wire=5

AZN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Astrazeneca Plc

The European Union has stepped up tough rules on the exports of Covid vaccines, while also piling pressure on AstraZeneca to deliver more shots to the region.

EU steps up vaccine exports rules and pressures AstraZeneca over deliveries

AstraZeneca PLC (LON:AZN) was urged to catch up with COVID-19 vaccine deliveries by the EU. "The company.

AstraZeneca urged to catch up with COVID-19 vaccine deliveries by EU chief

AstraZeneca (AZN) reports new efficacy data for its COVID-19 vaccine in the Unites States following criticism for providing outdated data.

AstraZeneca (AZN) Reports New Efficacy Data on COVID-19 Vaccine

New York, New York--(Newsfile Corp. - March 25, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Astrazeneca Plc ("Astrazeneca") (NASDAQ: AZN) between May 21, 2020 and November 20, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more information...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Astrazeneca Plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 29, 2021 - AZN

Nasal spray vaccines are easier to administer, avoid needles and can even provide better protection against infection.

Nasal Spray Of Covid Vaccine May Be Next: Oxford Reportedly To Test AstraZeneca Version

India has blocked all major exports of the AstraZeneca vaccine to boost domestic supply, the latest move by a country to stop doses from leaving its borders. This could disrupt the rollout of vaccines to poorer countries via the COVAX scheme, which had been counting on Indian-made doses.

India is blocking exports of AstraZeneca vaccines to use for itself, disrupting vaccine rollouts in other countries

AstraZeneca stock rose Thursday after the company said its coronavirus vaccine was 76% effective in a primary analysis of its U.S. final-phase test. It plans to soon ask for authorization.

AstraZeneca's Covid-19 Vaccine Saga Continues With A New Analysis

Los Angeles, California--(Newsfile Corp. - March 25, 2021) - Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive (the ''Class...

MONDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The shares of AstraZeneca plc (NASDAQ:AZN) have seen a lot of movement lately, with the drugmaker's Covid-19 vaccine popping up in the news  almost daily.

AstraZeneca Revises Vaccine Efficacy Rate, Stock Inches Higher

Denmark's health authority has extended its hold on using the AstraZeneca vaccine for another three weeks. "At this time, we believe that our basis for making a final decision on any future use of the COVID-19 vaccine from AstraZeneca is too uncertain.

Denmark extends suspension for using AstraZeneca vaccine for three weeks

AstraZeneca's Covid shot has always been accompanied by high hopes, but it has been mired in controversy ever since its inception.

Data, doubts and disputes: A timeline of AstraZeneca's Covid vaccine problems

AstraZeneca announced updated Phase 3 trial data of its Covid-19 vaccine, addressing concerns from a U.S. health agency about outdated interim data.

AstraZeneca Says Vaccine 76% Effective in Updated Trial Data and Plans to Seek U.S. Approval

After teaming up with Oxford University, AstraZeneca produced a safe and effective Covid-19 vaccine in just nine months, a huge achievement that will help end the pandemic. But a series of missteps along the way has led to scathing criticism from policymakers and health officials, tarnishing the company's image as a hero of the coronavirus era.

How a series of unforced errors tarnished AstraZeneca's image

AstraZeneca has updated its US COVID-19 vaccine trial results following concerns from Dr. Anthony Fauci and a panel of experts that the drugmaker had presented outdated data. The updated results, released Thursday, showed AstraZeneca's shot was 76% effective at protecting against symptomatic COVID-19, 15 days after the second dose of the two-dose vaccine. The company had said on Monday that the vaccine was 79% effective in the trial, which involved more than 32,000 people.

AstraZeneca revises down its vaccine efficacy in a huge US trial, from 79% to 76%, following concerns from Fauci and other experts that the results were outdated

NextEra Energy

A plunging market would be the opportune time to buy these superior stocks.

3 Perfect Stocks to Buy If the Stock Market Crashes

AstraZeneca PLC (LON:AZN) has published the primary results on Coronavirus (COVID-19) vaccine trials, which were consistent with the interim data published on Monday. The FTSE 100 pharma company said the jab showed 76% efficacy in preventing symptoms, 100% efficacy against severe or critical disease and hospitalisation and 85% efficacy against symptoms in participants aged 65 years and over.

AstraZeneca publishes primary COVID-19 vaccine trial results consistent with Monday data

AstraZeneca Plc (NASDAQ: AZN) on Wednesday issued a fresh update of its phase three trial data for the COVID-19 vaccine after a U.S. health agency earlier this week questioned the accuracy of the trial data. What Happened: The British drugmaker's latest update claims the vaccine developed with Oxford University is 76% effective in protecting against symptomatic cases of the virus, from 79% efficacy reported on Monday.

AstraZeneca Revises COVID-19 Vaccine Efficacy To 76% After Controversy

The new result reiterates the vaccine is 100% effective in preventing severe disease and hospitalization.

Revised U.S. Trials Numbers Show AstraZeneca Vaccine Is 76% Effective Against Symptomatic Covid-19

AstraZeneca PLC, which has been under fire for the accuracy of its data, on Wednesday night announced updated Phase 3 trial data of its coronavirus vaccine, saying it's 76% effective at preventing symptomatic COVID-19.

AstraZeneca now says its COVID-19 vaccine is 76% effective

AstraZeneca issued updated phase three trial data for its Covid-19 vaccine on Wednesday after facing criticism earlier this week over a preliminary report from its U.S. study.

AstraZeneca issues updated Phase 3 trial data for its Covid vaccine after facing criticism

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday, March 22, 2021. These results have been presented to the independent Data Safety Monitoring Board. The primary analysis is pre-specified in the protocol and will be the basis for a regulatory submission for Emergency Use Authorization to the US Food and Drug Adm

AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy

Inspection is fresh sign of breakdown in relations between Brussels and Anglo-Swedish vaccine supplier

News for AstraZeneca Stock (AZN)